Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis.
作者信息
Mastorino Luca, Siliquini Niccolò, Avallone Gianluca, Ortoncelli Michela, Quaglino Pietro, Dapavo Paolo, Ribero Simone
机构信息
Medical Science Department, Section of Dermatology, University of Turin, Italy.
出版信息
Dermatol Reports. 2022 Mar 17;14(3):9282. doi: 10.4081/dr.2022.9282. eCollection 2022 Sep 14.
Abstract
摘要
相似文献
1
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis.七名接受古塞库单抗治疗中度至重度银屑病的癌症患者。
Dermatol Reports. 2022 Mar 17;14(3):9282. doi: 10.4081/dr.2022.9282. eCollection 2022 Sep 14.
2
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.中度至重度斑块状银屑病患者中，ixekizumab与guselkumab的头对头比较：一项随机双盲试验的12周疗效、安全性及反应速度
Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15.
3
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.古塞单抗（一种针对 IL-23 的 mAb）可使中重度斑块状银屑病患者获得临床和分子应答。
J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.
4
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.古塞库单抗与司库奇尤单抗治疗中重度银屑病（ECLIPSE）：一项 3 期随机对照临床试验的结果。
Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8.
5
Guselkumab for the treatment of moderate-to-severe plaque psoriasis.古塞库单抗用于治疗中度至重度斑块状银屑病。
Expert Rev Clin Pharmacol. 2018 Apr;11(4):333-344. doi: 10.1080/17512433.2018.1445967. Epub 2018 Mar 6.
6
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis.开发并验证免疫分析法，以监测中重度银屑病患者古塞单抗及其抗古塞单抗抗体。
J Pharm Biomed Anal. 2020 Sep 10;189:113433. doi: 10.1016/j.jpba.2020.113433. Epub 2020 Jun 18.
7
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.中度至重度斑块状银屑病患者中，依奇珠单抗与古塞库单抗的头对头比较：一项随机双盲试验的24周疗效和安全性结果。
Br J Dermatol. 2021 Jun;184(6):1047-1058. doi: 10.1111/bjd.19509. Epub 2020 Oct 25.
8
Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.中度至重度斑块状银屑病合并潜伏性结核患者同时接受古塞库单抗和抗结核治疗的安全性：3期VOYAGE 1和VOYAGE 2试验汇总结果
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1744-1749. doi: 10.1111/jdv.16460. Epub 2020 May 15.
9
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).在初治的中重度斑块状银屑病患者中，古塞库单抗优于富马酸酯：一项随机、活性对照的IIIb期试验（POLARIS）结果
Br J Dermatol. 2020 Aug;183(2):265-275. doi: 10.1111/bjd.18696. Epub 2020 Jan 20.
10
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.古塞单抗，一种抗白细胞介素-23 单克隆抗体，用于治疗日本中重度斑块型银屑病患者：来自一项 3 期、随机、双盲、安慰剂对照研究的疗效和安全性结果。
J Dermatol. 2018 Sep;45(9):1053-1062. doi: 10.1111/1346-8138.14504. Epub 2018 Jun 15.
引用本文的文献
1
Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab.接受古塞库单抗治疗的恶性肿瘤合并中重度银屑病患者的真实世界疗效
JAAD Int. 2024 Apr 7;16:66-71. doi: 10.1016/j.jdin.2024.02.019. eCollection 2024 Sep.
2
A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review.多学科方法治疗患有银屑病和恶性肿瘤病史或正在接受实体瘤治疗的患者：叙述性文献综述。
Int J Mol Sci. 2023 Dec 16;24(24):17540. doi: 10.3390/ijms242417540.
3
A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders.对诊断为恶性肿瘤后接受生物疗法治疗皮肤病的患者的管理进行回顾性研究。
JAAD Case Rep. 2023 Jul 17;39:81-87. doi: 10.1016/j.jdcr.2023.07.007. eCollection 2023 Sep.
4
The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature.白细胞介素-23抑制剂用于治疗免疫检查点抑制剂诱导的免疫相关性银屑病及活动性癌症患者：病例系列及文献综述
SAGE Open Med Case Rep. 2023 Jun 16;11:2050313X231181035. doi: 10.1177/2050313X231181035. eCollection 2023.
本文引用的文献
1
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review.白细胞介素-17A 抑制剂在慢性斑块状银屑病合并恶性肿瘤病史患者中的应用：一项病例系列研究并系统性文献复习。
Dermatol Ther. 2021 Mar;34(2):e14889. doi: 10.1111/dth.14889. Epub 2021 Feb 25.
2
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.欧洲皮肤病学会关于寻常型银屑病系统治疗指南 - 第 2 部分：特殊临床和合并症情况。
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):281-317. doi: 10.1111/jdv.16926.
3
Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer.用古塞库单抗治疗一名非小细胞肺癌患者的寻常型银屑病。
Eur J Dermatol. 2020 Oct 1;30(5):609-611. doi: 10.1684/ejd.2020.3860.
4
New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers.白介素-12 和白介素-23 的新认识：从分子基础到免疫介导的炎症和癌症中的临床应用。
Biochem Pharmacol. 2020 May;175:113928. doi: 10.1016/j.bcp.2020.113928. Epub 2020 Mar 23.
5
6
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.白细胞介素（IL）-12/23和IL-17抑制剂优特克单抗、司库奇尤单抗、依奇珠单抗、布罗达单抗、古塞库单抗和替拉珠单抗治疗中度至重度斑块状银屑病疗效和安全性的系统评价与荟萃分析
J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28.
7
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗治疗中重度斑块状银屑病的疗效和安全性比较：来自 III 期、双盲、安慰剂和阳性对照的 VOYAGE 2 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2.
Zotero 插件